3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
3
Observational
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Neoplasms
1
Mycosis Fungoides
1
Lymphoma, T-Cell, Cutaneous
1
Interventions
Blood Specimen Collection
22
Surveys and Questionnaires
19
Nivolumab
14
Ipilimumab
12
pembrolizumab
11
Gene Expression Profiling
11
Biopsy
10
trametinib
9
dabrafenib
8
Flow Cytometry
8
Specimen Handling
7
Polymerase Chain Reaction
7
Tomography, Optical Coherence
6
Therapeutics
6
Immunohistochemistry
6
Imiquimod
6
Amplified Fragment Length Polymorphism Analysis
6
Watchful Waiting
5
Psychiatric Rehabilitation
5
Immunotherapy
5
Data Collection
5
3-ingenyl angelate
5
Mohs Surgery
4
Microarray Analysis
4
Interviews as Topic
4
Immunoenzyme Techniques
4
Drug Therapy
4
Dermoscopy
4
sonidegib
3
encorafenib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Amines
×
Dermatologic
×
Clear all
NCT02296164
2020-03-04
PROVe
Helsinn Therapeutics (U.S.), Inc
Completed
300 enrolled
7 charts